HIV-1 Antagonism of CD317 Is Species Specific and Involves Vpu-Mediated Proteasomal Degradation of the Restriction Factor

Bartee, 2006, Quantitative membrane proteomics reveals new cellular targets of viral immune modulators, PLoS Pathog., 2, e107, 10.1371/journal.ppat.0020107 Bieniasz, 2004, Intrinsic immunity: a front-line defense against viral attack, Nat. Immunol., 5, 1109, 10.1038/ni1125 Blasius, 2006, Bone marrow stromal cell antigen 2 is a specific marker of type I IFN-producing cells in the naive mouse, but a promiscuous cell surface antigen following IFN stimulation, J. Immunol., 177, 3260, 10.4049/jimmunol.177.5.3260 Bour, 1996, The envelope glycoprotein of human immunodeficiency virus type 2 enhances viral particle release: a Vpu-like factor?, J. Virol., 70, 820, 10.1128/JVI.70.2.820-829.1996 Bour, 1999, Lack of effect of cytoplasmic tail truncations on human immunodeficiency virus type 2 ROD env particle release activity, J. Virol., 73, 778, 10.1128/JVI.73.1.778-782.1999 Browne, 2008, Species-specific restriction of apobec3-mediated hypermutation, J. Virol., 82, 1305, 10.1128/JVI.01371-07 Chiu, 2008, The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements, Annu. Rev. Immunol., 26, 317, 10.1146/annurev.immunol.26.021607.090350 Fackler, 2006, Functional characterization of HIV-1 Nef mutants in the context of viral infection, Virology, 351, 322, 10.1016/j.virol.2006.03.044 Fenteany, 1995, Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin, Science, 268, 726, 10.1126/science.7732382 Geuenich, 2008, Aqueous extracts from peppermint, sage and lemon balm leaves display potent anti-HIV-1 activity by increasing the virion density, Retrovirology, 5, 27, 10.1186/1742-4690-5-27 Goff, 2004, Retrovirus restriction factors, Mol. Cell, 16, 849, 10.1016/j.molcel.2004.12.001 Goila-Gaur, 2008, HIV-1 Vif, APOBEC, and intrinsic immunity, Retrovirology, 5, 51, 10.1186/1742-4690-5-51 Goto, 1994, A novel membrane antigen selectively expressed on terminally differentiated human B cells, Blood, 84, 1922, 10.1182/blood.V84.6.1922.1922 Göttlinger, 1993, Vpu protein of human immunodeficiency virus type 1 enhances the release of capsids produced by gag gene constructs of widely divergent retroviruses, Proc. Natl. Acad. Sci. USA, 90, 7381, 10.1073/pnas.90.15.7381 Hannemann, 2008, The Diaphanous-related Formin FHOD1 associates with ROCK1 and promotes Src-dependent plasma membrane blebbing, J. Biol. Chem., 283, 27891, 10.1074/jbc.M801800200 Iida, 1999, Compatibility of Vpu-like activity in the four groups of primate immunodeficiency viruses, Virus Genes, 18, 183, 10.1023/A:1008041323852 Ishikawa, 1995, Molecular cloning and chromosomal mapping of a bone marrow stromal cell surface gene, BST2, that may be involved in pre-B-cell growth, Genomics, 26, 527, 10.1016/0888-7543(95)80171-H Keppler, 2002, Progress toward a human CD4/CCR5 transgenic rat model for de novo infection by human immunodeficiency virus type 1, J. Exp. Med., 195, 719, 10.1084/jem.20011549 Keppler, 2005, Rodent cells support key functions of the human immunodeficiency virus type 1 pathogenicity factor Nef, J. Virol., 79, 1655, 10.1128/JVI.79.3.1655-1665.2005 Klimkait, 1990, The human immunodeficiency virus type 1-specific protein Vpu is required for efficient virus maturation and release, J. Virol., 64, 621, 10.1128/JVI.64.2.621-629.1990 Kupzig, 2003, Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology, Traffic, 4, 694, 10.1034/j.1600-0854.2003.00129.x Malim, 2008, HIV-1 accessory proteins—ensuring viral survival in a hostile environment, Cell Host Microbe, 3, 388, 10.1016/j.chom.2008.04.008 Mariani, 2003, Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif, Cell, 114, 21, 10.1016/S0092-8674(03)00515-4 Neil, 2006, HIV-1 Vpu promotes release and prevents endocytosis of nascent retrovirus particles from the plasma membrane, PLoS Pathog., 2, e39, 10.1371/journal.ppat.0020039 Neil, 2007, An interferon-alpha-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein, Cell Host Microbe, 2, 193, 10.1016/j.chom.2007.08.001 Neil, 2008, Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu, Nature, 451, 425, 10.1038/nature06553 Nguyen, 2004, Codon optimization of the HIV-1 vpu and vif genes stabilizes their mRNA and allows for highly efficient Rev-independent expression, Virology, 319, 163, 10.1016/j.virol.2003.11.021 Noble, 2006, Recruitment of the adaptor protein 2 complex by the human immunodeficiency virus type 2 envelope protein is necessary for high levels of virus release, J. Virol., 80, 2924, 10.1128/JVI.80.6.2924-2932.2006 Pfeiffer, 2006, Effects of signal peptide exchange on HIV-1 glycoprotein expression and viral infectivity in mammalian cells, FEBS Lett., 580, 3775, 10.1016/j.febslet.2006.05.070 Ritter, 1996, Human immunodeficiency virus type 2 glycoprotein enhancement of particle budding: role of the cytoplasmic domain, J. Virol., 70, 2669, 10.1128/JVI.70.4.2669-2673.1996 Sakuma, 2007, Rhesus monkey TRIM5alpha restricts HIV-1 production through rapid degradation of viral Gag polyproteins, Nat. Med., 13, 631, 10.1038/nm1562 Schubert, 1994, The human immunodeficiency virus type 1 encoded Vpu protein is phosphorylated by casein kinase-2 (CK-2) at positions Ser52 and Ser56 within a predicted alpha-helix-turn-alpha-helix-motif, J. Mol. Biol., 236, 16, 10.1006/jmbi.1994.1114 Schubert, 1995, Augmentation of virus secretion by the human immunodeficiency virus type 1 Vpu protein is cell type independent and occurs in cultured human primary macrophages and lymphocytes, J. Virol., 69, 7699, 10.1128/JVI.69.12.7699-7711.1995 Schubert, 1999, Regulation of virus release by the macrophage-tropic human immunodeficiency virus type 1 AD8 isolate is redundant and can be controlled by either Vpu or Env, J. Virol., 73, 887, 10.1128/JVI.73.2.887-896.1999 Schubert, 2000, Proteasome inhibition interferes with gag polyprotein processing, release, and maturation of HIV-1 and HIV-2, Proc. Natl. Acad. Sci. USA, 97, 13057, 10.1073/pnas.97.24.13057 Sebastian, 2007, The Retroviral Restriction Factor TRIM5alpha, Curr. Infect. Dis. Rep., 9, 167, 10.1007/s11908-007-0013-4 Simon, 1998, Evidence for a newly discovered cellular anti-HIV-1 phenotype, Nat. Med., 4, 1397, 10.1038/3987 Stopak, 2003, HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability, Mol. Cell, 12, 591, 10.1016/S1097-2765(03)00353-8 Strebel, 2007, HIV accessory genes Vif and Vpu, Adv. Pharmacol., 55, 199, 10.1016/S1054-3589(07)55006-4 Towers, 2007, The control of viral infection by tripartite motif proteins and cyclophilin A, Retrovirology, 4, 40, 10.1186/1742-4690-4-40 Uchil, 2008, TRIM E3 ligases interfere with early and late stages of the retroviral life cycle, PLoS Pathog., 4, e16, 10.1371/journal.ppat.0040016 Van Damme, 2008, The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein, Cell Host Microbe, 3, 245, 10.1016/j.chom.2008.03.001 Vartanian, 2008, Evidence for editing of human papillomavirus DNA by APOBEC3 in benign and precancerous lesions, Science, 320, 230, 10.1126/science.1153201 Varthakavi, 2003, Viral protein U counteracts a human host cell restriction that inhibits HIV-1 particle production, Proc. Natl. Acad. Sci. USA, 100, 15154, 10.1073/pnas.2433165100 Varthakavi, 2006, The pericentriolar recycling endosome plays a key role in Vpu-mediated enhancement of HIV-1 particle release, Traffic, 7, 298, 10.1111/j.1600-0854.2005.00380.x Varthakavi, 2008, Identification of calcium-modulating cyclophilin ligand as a human host restriction to HIV-1 release overcome by Vpu, Nat. Med., 14, 641, 10.1038/nm1778 Wolf, 2007, TRIM28 mediates primer binding site-targeted silencing of murine leukemia virus in embryonic cells, Cell, 131, 46, 10.1016/j.cell.2007.07.026